IMGN earnings

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billionAbbVie to hold an investor conference call at 8:00 a.m. CTNORTH CHICAGO

Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer Conference Call to be Held at 8:00 a.m. E

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN

Continued Strong Momentum with ELAHERE Launch in US; Net Sales of $77.4 Million in Q2 Presented Positive Results for ELAHERE from Phase 3 MIRASOL Trial During Late-Breaking Oral Presentation at ASCO; First Therapy to Demonstrate an Overall Survival Benefit Compared to Chemotherapy in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Submission of ELAHERE MAA to Support Expansion into Europe and sBLA for Potential Full Approval in US on Track for Q4 2023 Presented Interim Analysis from Phase 2 CADENZA Trial at EHA Congress Showing Encouraging Anti-Tumor Activity and Durable Responses for Pivekimab Sunirine in BPDCN; Pivotal Frontline Cohort Now Fully Enrolled Generated $350.8 Mill

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGe

Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Conference Call to be Held at 8:00 AM ET Today ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-po

Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full Quarter of Launch Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Early May; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Announced Non-Dilutive Financing for Up to $175 Million to Strengthen Balance Sheet and Support Company's Growth Trajectory Expanded Leadership Team with the Appointment of Isabel Kalofonos as Senior Vice President and Chief Commercial Officer Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent prog

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN Immu

Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2 2023; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Encouraging Safety and Efficacy Data from Pivekimab Sunirine Triplet in AML Presented in Oral Session at ASH 2022; Clinical Collaboration with Gilead Announced to Evaluate Pivekimab with Magrolimab in Relapsed/Refractory AML Announced a Global, Multi-Target License and Option Agreement of ImmunoGen's ADC Tech

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developin

ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the Companion Diagnostic to Identify Ovarian Cancer Patients Eligible for ELAHERE, Contemporaneously Approved by FDA Approval Transitions ImmunoGen to a Fully-Integrated Oncology Company Conference Call to be Held Tomorrow at 8:00 AM ET ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval for E

Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date Presentations at ESMO, IGCS, and ESGO Highlight Mirvetuximab's Potential to Become New Standard of Care and Combination Agent of Choice in FRα-Positive Ovarian Cancer Initial Data from Pivotal Phase 2 CADENZA Study Demonstrated Encouraging Activity and Favorable Tolerability of Pivekimab Sunirine in Frontline BPDCN Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022. "With approva

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its third quarter 2022 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGe

Review of Data from First 10 Patients Demonstrates Significant Activity and Favorable Tolerability in Both De Novo BPDCN Patients and Those with a Prior or Concomitant Hematologic Malignancy (PCHM) Following Discussion with FDA, CADENZA Patients to be Segmented into De Novo and PCHM BPDCN Patients; Aligned with FDA on Efficacy Analysis in De Novo Patients Additional De Novo Patients to be Enrolled with Top-line Data Expected in 2024 Continuing to Enroll Patients with PCHM to Further Explore the Potential Benefit of Pivekimab in this Population Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADC

BLA for Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer Accepted by FDA with Priority Review; PDUFA Date Set for November 28, 2022 Completed enrollment in the Confirmatory MIRASOL Study Presented Additional Efficacy and Safety Data for Mirvetuximab Monotherapy at ASCO; Poster Highlighting Updated SORAYA Data Selected for Best of ASCO® Program Announced Multi-Year Collaboration with Oxford BioTherapeutics to Research and Develop Novel ADCs Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financi

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its second quarter 2022 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGe

Submitted BLA for Mirvetuximab Soravtansine Monotherapy to FDA Under Accelerated Approval Pathway; Commercial Preparations Underway Presented Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer in Plenary Session at SGO Annual Meeting; Additional Efficacy and Safety Data to be Highlighted at ASCO Top-Line Data from Confirmatory MIRASOL Trial Now Expected in Early 2023 Based on Recent Reforecast of Projected PFS Events Progressing Second Pivotal Program, Pivekimab Sunirine, with Top-Line Data in BPDCN Anticipated Before Year-End; Enrollment Ongoing in Phase 1b/2 Expansion Triplet Cohorts in AML Conference Call to be Held at 8:00 a.m. ET Today Immuno

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, dial (877) 621-5803; the conference ID is 5444669. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developing the next generatio

Positive Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer; Detailed Results to be Presented in Plenary Session at SGO in March Mirvetuximab BLA On Track for Submission this Quarter IMGN632 Triplet Data Demonstrating Manageable Safety Profile and Encouraging Activity in AML Highlighted in Oral Presentation at ASH 2021; Top-Line Data from Pivotal CADENZA Trial of IMGN632 in BPDCN Expected in H2 2022 Appointments of Chief Commercial Officer and Head of Medical Affairs Support Transition to a Fully-Integrated Oncology Company Ended 2021 with over $475 Million of Cash on the Balance Sheet, Extending Anticipated Cash Runway into 2024 Conference Call to

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, dial (877) 621-5803; the conference ID is 5566069. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antib

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4% Median Duration of Response at Data Cutoff is 5.9 Months Continued Demonstration of Favorable Tolerability Profile BLA Submission on Track for First Quarter of 2022 Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated wi

Top-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting PICCOLO, Single-Arm Study of Mirvetuximab in Platinum-Sensitive Ovarian Cancer, Open for Enrollment Earlier-Stage Pipeline Continues to Progress Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2021. "We look forward to announcing top-l

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, dial (877) 621-5803; the conference ID is 1587202. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developing the next generation

Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release Continued Progress in Ongoing MIRASOL, IMGN632, and IMGC936 Studies Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2021. "With top-line data from our pivotal SORAYA trial on track for release in Q4, we have accelerated